Clinical Trials Have a Data Supply Problem. The Patients Are There. The Infrastructure Isn't.

Every clinical trial has two fundamental requirements: enough patients to reach statistical significance, and enough confidence in those patients' data to trust the results.

Most trials struggle with both.

The patients exist. For almost every study, somewhere in the health system, there are people who meet the inclusion criteria, whose data would support the research, who might benefit from participation. The challenge is not the supply. The challenge is the infrastructure that would let a researcher find those patients, verify the quality of their data, confirm the consent, and create a defensible cohort.

That infrastructure does not exist at scale. And its absence is why clinical trials cost what they cost, take as long as they take, and fail as often as they do.

The supply and demand mismatch

Think about the clinical trial pipeline as a supply and demand problem.

The demand side is well-defined: researchers need specific patient populations, with specific data profiles, at sufficient scale to produce statistically significant results. The inclusion and exclusion criteria are documented. The required sample size is calculable. The demand is specific and measurable.

The supply side is a black box. The patients exist in health systems, in registries, in direct-to-consumer health platforms, in rare disease communities. Their data exists in EMRs, in lab systems, in wearables, in patient-reported outcomes. But the supply has no common trust standard.

A researcher cannot look at a potential patient population and ask: is this data accurate? Is it current? Is it consented for research use? How was it captured and by whom? Without answers to those questions, the supply cannot be matched to the demand. The researcher defaults to rebuilding the cohort from scratch, at their own institution, at enormous cost in time and money.

What a trust layer makes possible

The SuperTruth Data Trust Index makes the supply side legible.

Every data record scored by the DTI carries its provenance, its consent authorization, its recency, and its quality assessment as a permanent, queryable attribute. A researcher can specify a minimum DTI tier — Bronze, Silver, Gold, or Platinum — and filter a patient population to only those whose data meets that threshold.

For oncology research, VIOLET maps the behavioral signal layer: which patient communities are actively searching for clinical trial options, which rare disease cohorts are engaged and motivated, which populations are underserved by current trial recruitment approaches. The behavioral data runs twelve to eighteen months ahead of clinical presentation — which means researchers can identify cohorts before those patients are enrolled in competing trials or lost to the system.

ConsentOS provides the consent infrastructure. The difference between implied consent and explicit research consent is documented, tracked, and provable in an audit. When the FDA reviews the trial's data provenance, every consent decision is on record.

The fragmentation cost

The direct cost of inadequate clinical trial data infrastructure is measured in trial failure rates, extended timelines, and per-patient recruitment costs that now routinely exceed tens of thousands of dollars for common conditions and far more for rare diseases.

The indirect cost is harder to measure: the research that never happens because the cohort is too expensive to build, the therapy that reaches patients years later than it should, the patient who did not know a relevant trial existed because there was no mechanism to find them.

The clinical trial data problem is not a research problem. It is a data trust problem. The patients are there. The supply needs a trust layer before the demand can find it.

Further reading: See our oncology intelligence solution To learn more, reach Louis Simeonidis at louis@supertruth.ai or (215) 918-4140.